Overview

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label study to evaluate the safety and efficacy of ZG005 in combination with Donafenib or Bevacizumab in patients with advanced hepatocellular carcinoma.
Phase:
NA
Details
Lead Sponsor:
Changsha Taihe Hospital
Treatments:
Bevacizumab
donafenib
Injections